Additionally, it was found that EGFR plays an important role in non-malignant disorders and EGFR inhibitors attenuate the metabolic diseases both in vivo and in vitro studies through anti-inflammatory and anti-oxidative actions [10–13]. This evidence concerns the gene EGFR and Other metabolic disease.